Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 120

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 120
---
 announcements by us or third parties, including our filings with the SEC; |

| ● | publication of research reports about us or our industry, or microbiome therapies in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; |

| ● | guidance, if any, that we provide to the public, any changes in this guidance or our failure to meet this guidance; |

| ● | changes in the market valuations of similar companies; |

| ● | overall performance of the equity markets; |

| ● | sales of our Common Stock by us or our stockholders, in the future; |

| ● | trading volume of our Common Stock; |

| ● | investor perceptions of the investment opportunity associated with our Common Stock relative to other investment alternatives; |

| ● | actions by institutional or activist stockholders; |

| ● | change in accounting standards, policies, guidelines, interpretations or principles; |

| ● | ineffectiveness of our internal controls; |

63

| ● | disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; |

| ● | significant lawsuits, including patent or stockholder litigation; |

| ● | changes in the structure of healthcare payments systems; |

| ● | issuance of additional shares of our Common Stock to comply with the full ratchet antidilution rights contained in our outstanding Warrants; |

| ● | failure to raise additional funds on acceptable terms, or at all; |

| ● | changes in business or regulatory conditions, including new laws or regulations or new interpretations of existing laws or regulations applicable to our business; |

| ● | general political, economic, industry and market conditions, including rising interest rates and inflation; and |

| ● | other events or factors, many of which are beyond our control. |

In addition, the stock market in general, and the markets for special purpose acquisition company post-business combination businesses and healthcare companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our Common Stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float and trading volume of our Common Stock is low. If the market price of our Common Stock falls, you may not realize any return on your investment and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in